Lipocine Inc (LPCN) - Total Liabilities
Based on the latest financial reports, Lipocine Inc (LPCN) has total liabilities worth $1.93 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Lipocine Inc cash conversion from operations to assess how effectively this company generates cash.
Lipocine Inc - Total Liabilities Trend (2011–2024)
This chart illustrates how Lipocine Inc's total liabilities have evolved over time, based on quarterly financial data. Check LPCN asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Lipocine Inc Competitors by Total Liabilities
The table below lists competitors of Lipocine Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Vesuvius PLC
LSE:VSVS
|
UK | GBX1.16 Billion |
|
Scandinavian Medical Solutions AS
CO:SMSMED
|
Denmark | Dkr123.19 Million |
|
Thunderful Group AB
ST:THUNDR
|
Sweden | Skr172.90 Million |
|
Breedon Group PLC
LSE:BREE
|
UK | GBX1.21 Billion |
|
Flour Mills Kepenos S.A.
AT:KEPEN
|
Greece | €45.05 Million |
|
Cadrenal Therapeutics, Inc. Common Stock
NASDAQ:CVKD
|
USA | $1.35 Million |
|
Golden Land Bhd
KLSE:7382
|
Malaysia | RM201.14 Million |
Liability Composition Analysis (2011–2024)
This chart breaks down Lipocine Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Lipocine Inc (LPCN) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.25 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lipocine Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lipocine Inc (2011–2024)
The table below shows the annual total liabilities of Lipocine Inc from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $1.51 Million | -42.51% |
| 2023-12-31 | $2.63 Million | +37.93% |
| 2022-12-31 | $1.91 Million | -72.40% |
| 2021-12-31 | $6.91 Million | -30.95% |
| 2020-12-31 | $10.01 Million | -25.13% |
| 2019-12-31 | $13.37 Million | +17.10% |
| 2018-12-31 | $11.42 Million | +79.95% |
| 2017-12-31 | $6.35 Million | +378.46% |
| 2016-12-31 | $1.33 Million | -60.90% |
| 2015-12-31 | $3.39 Million | +107.64% |
| 2014-12-31 | $1.63 Million | +27.24% |
| 2013-12-31 | $1.28 Million | +10694.37% |
| 2012-12-31 | $11.89K | +56.38% |
| 2011-12-31 | $7.61K | -- |
About Lipocine Inc
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include LPCN 1111 (TLANDO XR), a next-generation lon… Read more